Sotagliflozin

Sotagliflozin, sold under the brand name Zynquista, is a drug approved in the European Union for people with type 1 diabetes.[2][1][3]

Sotagliflozin
Clinical data
Trade namesZynquista
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • EU: Rx-only [1]
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.231.837
Chemical and physical data
FormulaC21H25ClO5S
Molar mass424.94 g·mol−1
3D model (JSmol)
SMILES
  • CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)SC)O)O)O)Cl
InChI
  • InChI=1S/C21H25ClO5S/c1-3-26-15-7-4-12(5-8-15)10-14-11-13(6-9-16(14)22)20-18(24)17(23)19(25)21(27-20)28-2/h4-9,11,17-21,23-25H,3,10H2,1-2H3/t17-,18-,19+,20+,21-/m1/s1
  • Key:QKDRXGFQVGOQKS-CRSSMBPESA-N

The most common side effect is genital infection in women.[1] Other common side effects include diabetic ketoacidosis, diarrhoea and genital infection in men.[1]

The US Food and Drug Administration (FDA) refused its approval for use in combination with insulin for the treatment of type 1 diabetes. It is developed by Lexicon Pharmaceuticals.[4][5][6]

Sotagliflozin is a combination sodium/glucose cotransporter 1 and 2 (SGLT1/2) inhibitor and is in the class of drugs known as gliflozins.

References
  1. "Zynquista EPAR". European Medicines Agency (EMA). 27 February 2019. Retrieved 28 October 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  2. Zynquista approved in EU for certain patients with type I diabetes
  3. Chatzopoulos G, Tziomalos K (October 2020). "An up-to-date evaluation of sotagliflozin for the treatment of type 1 diabetes". Expert Opinion on Pharmacotherapy. 21 (15): 1799–1803. doi:10.1080/14656566.2020.1793961. PMID 33108240. S2CID 225098786.
  4. "Sotagliflozin as an Adjunct to Insulin for Type 1 Diabetes" (PDF). U.S. Food and Drug Administration (FDA).
  5. "Sanofi: FDA advisory committee votes on Zynquista (sotagliflozin) as treatment for adults with type 1 diabetes" (Press release). Sanofi. 17 January 2019 – via GlobeNewswire.
  6. "Sanofi: FDA advisory committee votes on Zynquista (sotagliflozin) as treatment for adults with type 1 diabetes". Sanofi (Press release). 18 January 2019. Retrieved 28 October 2020.
  • "Sotagliflozin". Drug Information Portal. U.S. National Library of Medicine.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.